Feb. 23, 2021—Vanderbilt researchers have linked bone-related complications of severely injured patients — findings that could help minimize these complications.
Feb. 18, 2021—Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.
Feb. 11, 2021—David Merryman has discovered that targeting a protein receptor in heart cells may limit a heart attack’s acute and long-term effects.
Jan. 25, 2021—A blood stem cell protein plays a role in the initiation and progression of leukemia, Vanderbilt researchers have found.
Jan. 12, 2021—Oxidative stress and toxic products called isolevuglandins in mitochondria play a role in endothelial dysfunction and hypertension — and getting rid of them with a special “scavenger” molecule has therapeutic potential.
Dec. 14, 2020—Vanderbilt researchers demonstrate that the polymer P188 has promise as a therapy to prevent reperfusion injury — the cellular damage that occurs when blood flow returns after an ischemic event like a heart attack.
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
Sep. 17, 2020—Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.
Aug. 20, 2020—Excess dietary salt activates immune cells to induce inflammation and hypertension, supporting current recommendations for low sodium consumption.
Jul. 27, 2020—Consumption of soy foods may shape the microbiome and protect against hypertension only in individuals with soy-responsive microbiota, Vanderbilt researchers have discovered.
Jun. 24, 2020—The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19.